U.S., Jan. 31 -- ClinicalTrials.gov registry received information related to the study (NCT07377526) titled 'Phase 1/2 Study TROP2 CAREngineered Cord Blood-Derived NK Cells + Belzutifan In Pancreatic Cancer' on Jan. 26.
Brief Summary: This is a Phase I/II study evaluating the intraperitoneal delivery of TROP2 CAR/IL-15 TGFBR2 KO NK cells in combination with oral belzutifan (120 mg daily) for patients with recurrent, locally advanced, unresectable and metastatic pancreatic cancer. The primary objectives are to assess safety and determine the recommended Phase II dose (RP2D).
Study Start Date: July 01, 2026
Study Type: INTERVENTIONAL
Condition:
Pancreatic Cancer
Intervention:
DRUG: TGFBR2 KO CAR27/IL-15 NK cells
Given by mouth
Recrui...